Triple
T21327540
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Larry Bock |
E525800
|
entity |
| Predicate | coFounded |
P104
|
FINISHED |
| Object | Idun Pharmaceuticals |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Idun Pharmaceuticals | Statement: [Larry Bock, coFounded, Idun Pharmaceuticals]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Idun Pharmaceuticals Context triple: [Larry Bock, coFounded, Idun Pharmaceuticals]
-
A.
Idera, Inc.
Idera, Inc. is a software company best known for its database management, performance monitoring, and developer tools used by IT professionals and enterprises.
-
B.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
-
C.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
D.
Millennium Pharmaceuticals
Millennium Pharmaceuticals is a biotechnology company known for developing innovative cancer therapies, including the proteasome inhibitor bortezomib (Velcade) for multiple myeloma.
-
E.
Innogen
Innogen is the original name of Imogen, the virtuous and wronged heroine of William Shakespeare’s play "Cymbeline."
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Idun Pharmaceuticals Target entity description: Idun Pharmaceuticals is a biotechnology company focused on developing therapies that regulate cell death pathways, particularly apoptosis, for the treatment of various diseases.
-
A.
Idera, Inc.
Idera, Inc. is a software company best known for its database management, performance monitoring, and developer tools used by IT professionals and enterprises.
-
B.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
-
C.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
D.
Millennium Pharmaceuticals
Millennium Pharmaceuticals is a biotechnology company known for developing innovative cancer therapies, including the proteasome inhibitor bortezomib (Velcade) for multiple myeloma.
-
E.
Innogen
Innogen is the original name of Imogen, the virtuous and wronged heroine of William Shakespeare’s play "Cymbeline."
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e0b51b90788190a4dd823d962626da |
completed | April 16, 2026, 10:08 a.m. |
| NER | Named-entity recognition | batch_69e7ab4d69b4819088649e34213d0b67 |
completed | April 21, 2026, 4:52 p.m. |
Created at: April 16, 2026, 4:41 p.m.